Article
Oncology
Yinghui Hong, Mingliang Ye, Fan Wang, Jun Fang, Chun Wang, Jie Luo, Jialiang Liu, Jing Liu, Lan Liu, Qiu Zhao, Ying Chang
Summary: This study reveals that miR-21-3p promotes migration and invasion of HCC cells and upregulates YAP1 expression by directly inhibiting SMAD7, highlighting a major epigenetic mechanism in HCC pathogenesis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Hongyuan Chen, Meng Kong, Ying Chen, Yugang Jiang, Mingxin Wen, Xinke Zhang
Summary: The study revealed that low expression of miR-203 was significantly associated with tumor recurrence and poor survival in patients with early-stage HCC, suggesting its potential as a novel predictor and molecular target for HCC therapy.
Retraction
Biochemistry & Molecular Biology
Baoxing Jia, Ludong Tan, Zhe Jin, Yan Jiao, Yu Fu, Yahui Liu
Summary: The article was retracted by agreement between the authors, the journal's Editor in Chief, Prof. Dr. Christian Behl, and Wiley Periodicals LLC due to unintentional errors occurred during the research process and inability to verify the experimental results.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2021)
Article
Cell Biology
Hui Hu, Wei Huang, Hong Zhang, Jianye Li, Qiong Zhang, Ya-Ru Miao, Fei-Fei Hu, Lu Gan, Zhenhong Su, Xiangliang Yang, An-Yuan Guo
Summary: The miR-9-5p/FOXO1/CPEB3 feed-forward loop was identified and found to play a critical role in the progression of hepatocellular carcinoma (HCC). This regulatory module could potentially serve as a new therapeutic target for HCC treatment.
Article
Oncology
Yuan Chen, Hao Xu, Hao Tang, Hongyuan Li, Chi Zhang, Shengjie Jin, Dousheng Bai
Summary: This study found that miR-9-5p can predict vascular invasion and prognosis in hepatocellular carcinoma (HCC) patients. Experimental results showed that downregulation of miR-9-5p inhibits migration, invasion, and angiogenesis of HCC cells. MiR-9-5p is an independent risk factor for HCC, and the nomogram based on miR-9-5p has a good predictive value for HCC survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Xiaobin Chi, Yi Jiang, Yongbiao Chen, Lizhi Lv, Jianwei Chen, Fang Yang, Xiaojin Zhang, Fan Pan, Qiucheng Cai
Summary: High expression of miR-652-3p in HCC is associated with clinical severity, and elevated levels may lead to poorer prognosis.
Article
Oncology
Shuangshuang Li, Jiajia Shao, Guohua Lou, Chao Wu, Yanning Liu, Min Zheng
Summary: The study uncovered the role of EIF4G2 in HCC development through ERK pathway activation. It was also found that EIF4G2 could be negatively regulated by the tumor suppressor miR-144. Investigations suggested that EIF4G2 might be a promising therapeutic target in HCC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Guanlin Zhou, Yijun Zeng, Yingmin Luo, Sheng Guo, Longyuan Bao, Qiong Zhang
Summary: miR-93-5p shows potential as a biomarker for early detection of HBV-related HCC. Urine miR-93-5p can also be used to predict the prognosis of patients with HBV-related HCC.
Review
Oncology
Tian-Run Lv, Hai-Jie Hu, Parbatraj Regmi, Fei Liu, Fu-Yu Li
Summary: Sarcomatoid hepatocellular carcinoma (SHCC) is a rare subtype of primary liver malignancies. Compared to conventional hepatocellular carcinoma (HCC), SHCC has worse prognosis and exhibits more aggressive behavior.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Jianting Long, Baoxian Liu, Zhijia Yao, Huiwen Weng, Heping Li, Chunlin Jiang, Shi Fang
Summary: miR-500a-3p may serve as a biomarker for hepatocellular carcinoma, with diagnostic and prognostic significance.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2022)
Article
Cell Biology
Tianxiang Chen, Runkun Liu, Yongshen Niu, Huanye Mo, Hao Wang, Ye Lu, Liang Wang, Liankang Sun, Yufeng Wang, Kangsheng Tu, Qingguang Liu
Summary: This study identified a novel lncRNA, KDM4A-AS1, which is highly expressed in HCC tissues and plays a crucial role in promoting tumor growth and metastasis by competitively binding miR-411-5p, thereby activating the AKT pathway. Additionally, KDM4A-AS1 was found to be regulated by hypoxia-inducible factor 1 alpha (HIF-1 alpha) through the KPNA2/AKT signaling pathway, providing a potential prognostic and therapeutic target for HCC.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Shuying Chen, Yinqi Mao, Wei Chen, Chenbin Liu, Han Wu, Jingjun Zhang, Shenghao Wang, Chengpan Wang, Yong Lin, Yuan Lv
Summary: This study found that serum exosomal miR-34a is significantly down-regulated in patients with hepatocellular carcinoma (HCC), and it may serve as a novel non-invasive biomarker for the diagnosis and prognosis of HCC.
Article
Environmental Sciences
Liguo Zhang, Ping Zhang, Tonggang Liu, Dongmei Li, Xianxian Liu
Summary: circ_0006404 is overexpressed in hepatocellular carcinoma (HCC) and promotes HCC cell growth, cycle, and migration. It functions by regulating the expression of miR-624. These findings suggest that circ_0006404 may serve as a new biomarker for HCC.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2022)
Article
Oncology
Zhongyuan Cui, Jielong Wang, Gang Chen, Dongliang Li, Bianqiao Cheng, Yanhua Lai, Zhixian Wu
Summary: This study aimed to identify potential novel prognostic markers and therapeutic targets for hepatocellular carcinoma (HCC). The upregulation of CLGN in HCC was significantly associated with poor prognosis, especially in advanced stages, and may be regulated by hsa-miR-194-3p. These findings suggest that CLGN may be closely related to the progression of HCC, and is a potential therapeutic target and prognostic indicator for patients with advanced HCC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
J. Peng, H. J. Wu, H. F. Zhang, S. Q. Fang, R. Zeng
Summary: In HCC cells, FGF1 is highly expressed while miR-143-3p is poorly expressed. Both indicators have AUCs > 0.8 and are correlated with patient characteristics. Silencing FGF1 and overexpressing miR-143-3p promote cell apoptosis, inhibit cell growth, EMT, and affect the expression of related proteins. Targeted relationship between FGF1 and miR-143-3p is confirmed and inhibiting FGF1 may become a potential therapeutic target for HCC.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)